Derazantinib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameDerazantinib
Drug Alias Name德拉替尼Derazantinib - Arcule/Basilea PharmaceuticaDerazantinib hydrochlorideARQ-087.2HClAQ-14741087 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionColony stimulating factor 1 receptor inhibitorsFibroblast growth factor receptor 2 antagonistsFibroblast growth factor receptor 1 antagonists +[5] 
TargetsColony stimulating factor 1 receptorFibroblast growth factor receptor 2Fibroblast growth factor receptor 1 +[5] 
Therapy Area/IndicationsSolid tumoursUrogenital NeoplasmsStomach Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesArqule Inc
China Registration ClassN/A

Develop Information

Active CompaniesBasilea PharmaceuticaSinovant Sciences Hk LtdMayne Pharma Inc +[5] 
Inactive CompaniesArqule Inc
Active IndicationsUrogenital NeoplasmsBiliary Tract NeoplasmsCarcinoma, Transitional Cell +[5] 
Inactive IndicationsSolid tumoursStomach Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A